OpenScience.ink

5 days ago • American journal of kidney diseases : the official journal of the National Kidney Foundation

Key Links Between Kidney and Digestive System DisordersThe Crossroads Between the Kidney and Gastrointestinal Disorders: Core Curriculum 2026.

🥉 Top 5% JournalArticle

5 days ago • Expert opinion on pharmacotherapy

Guidelines for Switching Between Semaglutide and Tirzepatide at Similar Effectiveness Levels in Obesity TreatmentSwitching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching doses.

📖 Top 30% JournalArticle

5 days ago • Rambam Maimonides medical journal

Brain and mental health safety of GLP-1 receptor drugs and tirzepatide in adults with type 2 diabetes or obesityNeuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide in Adults with Type 2 Diabetes Mellitus or Obesity.

📖 Top 50% JournalArticle

5 days ago • CNS spectrums

Differences between men and women in glucagon-like peptide-1 signaling and what it may mean for Alzheimer's diseaseSex differences in glucagon-like peptide-1 signalling and the implications for Alzheimer's disease: A narrative review.

📖 Top 20% JournalArticle

5 days ago • Diabetes, obesity & metabolism

Early use patterns and long-term continuation of semaglutide for obesity in a large populationEarly Treatment Trajectory and Long-Term Persistence to Semaglutide for Obesity: A Population-Based Cohort Study.

Article

6 days ago • BMC cardiovascular disorders

Comparing heart-related side effect patterns of GLP-1 receptor drugs using FDA reportsComparison of cardiac adverse event signal profiles for GLP-1 receptor agonists: an analysis of the FAERS database.

📖 Top 30% JournalComparative Study

6 days ago • Frontiers in pharmacology

Molecular insights into how GLP-1 receptor drugs work in type 2 diabetes and obesityInsights from multi-omics on GLP-1 receptor agonists in type 2 diabetes and obesity.

📖 Top 20% JournalArticle

6 days ago • Frontiers in pharmacology

Using dual and triple-target drugs as new treatments for fatty liver disease linked to metabolism problemsFrom pathophysiology to therapy: dual and triple agonists as a new frontier in metabolic dysfunction-associated steatotic liver disease.

📖 Top 20% JournalArticle

6 days ago • Health affairs scholar

Prescription denials for diabetes and weight-loss drugs under commercial, Medicare, and Medicaid plans from 2018 to 2024Prescription denials for GLP-1 receptor agonists across commercial, Medicare, and Medicaid coverage, 2018-2024.

Article

6 days ago • The Journal of clinical endocrinology and metabolism

Normal-Weight Fatty Liver Disease Linked to Higher Risk of Death, Heart Problems, Cancer, and Less Use of GLP-1 MedicationNormal-BMI MASLD is Associated with Increased Mortality, Cardiovascular Events, Cancer and Lower GLP-1 Use.

🥉 Top 5% JournalArticle

6 days ago • The Journal of international medical research

Severe acid imbalance linked to starvation after short-term use of oral semaglutide: A case reportStarvation-associated high-anion gap metabolic acidosis following short-term oral semaglutide use: A case report.

📖 Top 50% JournalCase Reports

6 days ago • Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists

A clinical approach to multiorgan incretin therapy based on receptor structure and treatment stageFrom receptor architecture to outcome maturity: a clinical framework for multiorgan incretin therapy.

Article

6 days ago • Diabetes, metabolic syndrome and obesity : targets and therapy

Effects of Incretin-Based Treatments on Body Measurements and Metabolism in Women with Polycystic Ovary SyndromeThe Impact of Incretin-Based Therapies on Anthropometric and Metabolic Parameters in Women with Polyendocrine Metabolic Ovarian Syndrome.

📖 Top 30% JournalArticle

6 days ago • Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace

Glucagon-like-peptide-1 receptor agonists and their impact on major heart and blood vessel health outcomesEffect of glucagon-like-peptide-1 receptor agonists on major cardiovascular outcomes: a systematic review and meta-analysis.

Article

6 days ago • Diabetes, metabolic syndrome and obesity : targets and therapy

Pancreatic and Gallbladder Problems Linked to Tirzepatide Use for ObesityPancreatic and Gallbladder Adverse Events Associated with Tirzepatide in Obesity Management: A Scoping Review.

📖 Top 30% JournalArticle

6 days ago • Diabetes care

A Controlled Study of Acmopatide, a Targeted Hormone Drug, in Overweight Adults with Type 1 DiabetesA Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Acmopatide (CT-868), a Fully Biased GLP-1/GIP Receptor Agonist, in Adults With Type 1 Diabetes and Overweight or Obesity.

Article

6 days ago • Medical care research and review : MCRR

Use of Glucagon-Like Peptide-1 Drugs Among Medicaid Patients: Findings From Policy and Prescription DataGlucagon-Like Peptide-1 Receptor Agonists and Medicaid: Insights From Policy and Prescription Data.

🎖️ Top 10% JournalArticle

6 days ago • British journal of pharmacology

Activating GLP-1 receptors reduces chronic migraine-like symptoms with different effects on opioid and cannabinoid systems in males and femalesGLP-1 receptor activation attenuates chronic migraine-like behaviour: Sex-specific modulation of opioid- and endocannabinoid-related pathways.

Article

6 days ago • Diabetes, obesity & metabolism

GLP-1 Treatment for Type 1 Diabetes: Balancing Benefits, Risks, and Choosing the Right PatientsGLP-1-Based Therapy in Type 1 Diabetes: Balancing Efficacy, Safety, and Patient Selection.

Article

6 days ago • Journal of diabetes science and technology

Multiple Health Effects of GLP-1 Receptor Agonists Compared to Other Treatments in Type 2 DiabetesMultisystem Outcomes of GLP-1 Receptor Agonists Versus Active Comparators in Type 2 Diabetes: A Multicenter Target Trial Emulation.

🎖️ Top 10% JournalArticle

6 days ago • Diabetes, obesity & metabolism

Tirzepatide led to significant weight loss over 12 months in people with obesity or overweightTirzepatide Use Resulted in Clinically Meaningful Weight Reduction in Individuals With Obesity or Overweight: 12-Month Real-World Results.

Article

6 days ago • Diabetes, obesity & metabolism

Article

6 days ago • Molecular metabolism

Ongoing CagriSema treatment keeps weight off by lowering food intake and keeping energy use steady in ratsContinued CagriSema treatment preserves weight loss by reducing energy intake and maintaining energy expenditure in rats.

🥉 Top 5% JournalArticle

6 days ago • Clinics in dermatology

How GLP-1 Receptor Agonists Affect Diabetic Foot Problems: Causes, Clinical Findings, and Treatment TipsGLP-1 Receptor Agonists and the Diabetic Foot: Mechanisms, Clinical Evidence, and Practical Considerations.

📖 Top 50% JournalArticle

1 week ago • Journal of the American Chemical Society

Using Mass Spectrometry to Reveal How Semaglutide Molecules Change Shape and Group TogetherStructural Mass Spectrometry Resolves the Conformational Dynamics of Semaglutide Oligomerization.

🥇 Top 1% JournalArticle

1 week ago • Pharmaceuticals (Basel, Switzerland)

How Plant Compounds Affect Blood Sugar After Eating by Targeting Digestive Enzymes and Blood Sugar-Regulating HormonesPlant-Derived Control of Postprandial Glycemia: α-Amylase, α-Glucosidase, and the Incretin-DPP-4 Interface.

📖 Top 20% JournalArticle

1 week ago • Medicina (Kaunas, Lithuania)

The Role of Stomach Balloons Compared to New Effective Obesity MedicinesDo Gastric Balloons Have a Future? Intragastric Balloons in the Era of Highly Effective Obesity Pharmacotherapy.

📖 Top 30% JournalArticle

1 week ago • Cureus

Possible link between tirzepatide use and reduced blood flow causing colon inflammationIschemic Colitis in the Setting of Tirzepatide Use: A Potentially Underrecognized Adverse Effect.

Case Reports

1 week ago • International journal of molecular sciences

Targeting multiple pathways beyond single GLP-1 drugs for precise treatment and lasting change in childhood obesityPrecision Pharmacotherapy for Childhood Obesity: Molecular Targets Beyond Single GLP-1 Receptor Agonism and a Framework for Disease Modification.

📖 Top 20% JournalArticle

1 week ago • Journal of clinical medicine

Mazdutide's effectiveness in treating GSD IXc: A case reportEffectiveness of the Dual GLP-1R/GCGR Agonist Mazdutide in GSD IXc: A Case Report.

📖 Top 20% JournalCase Reports

← prevpage 3 of 16next →

Latest GLP-1 Therapies Research Papers